Invex Therapeutics Limited (ASX:IXC) has disclosed the results of its Annual General Meeting held on 20 November 2026, at Level 3, 101 St Georges Terrace, Perth WA 6000, with all three resolutions carried by poll.
Key Points
- The Annual General Meeting was held on 20 November 2026 at 10am in Perth, Western Australia.
- The Remuneration Report was adopted with 98.62% of poll votes cast in favour.
- Professor Warren Harding AM was re-elected as a director with 99.86% of poll votes cast in favour.
- The 7.1A Mandate was approved with 99.47% of poll votes cast in favour.
Remuneration Report Adoption Result
Resolution 1, the adoption of the Remuneration Report, was decided by poll. A total of 21,042,560 votes were cast in favour, representing 98.62% of poll votes, while 294,783 votes were cast against, representing 1.38%. No votes were recorded as abstaining in the poll. Proxy votes cast in favour prior to the close of proxy voting totalled 21,032,560, equating to 98.57%, with 294,783 votes against at 1.38%, and 10,000 votes at the proxy's discretion.
Re-Election of Director Professor Warren Harding AM
Resolution 2, the re-election of Professor Warren Harding AM as a director, was decided by poll and carried. The poll recorded 21,306,613 votes in favour, representing 99.86% of votes cast, and 30,730 votes against, representing 0.14%. No abstentions were recorded in the poll. At the proxy voting close, 21,296,613 votes had been lodged in favour at 99.81%, with 30,730 votes against at 0.14%, and 10,000 votes at the proxy's discretion.
7.1A Mandate Approval
Resolution 3, the approval of the 7.1A Mandate, was decided by poll and carried. Poll results showed 21,224,113 votes in favour, representing 99.47%, and 113,230 votes against, representing 0.53%, with no abstentions recorded. Prior to the close of proxy voting, 21,214,113 votes had been lodged in favour at 99.42%, with 113,230 votes against at 0.53% and 10,000 votes at the proxy's discretion. Invex Therapeutics is a biopharmaceutical company focused on the repurposing of Exenatide, trademarked as Presendin™, for the treatment of neurological conditions involving raised intracranial pressure.


Please wait processing your request...